Laboratory Of America traded at $269.19 this Monday April 20th, decreasing $1.49 or 0.55 percent since the previous trading session. Looking back, over the last four weeks, Laboratory Of America lost 1.80 percent. Over the last 12 months, its price rose by 26.84 percent. Looking ahead, we forecast Laboratory Of America to be priced at 264.73 by the end of this quarter and at 247.63 in one year, according to Trading Economics global macro models projections and analysts expectations.
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers.